#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Optically active phthalocyanine ( Pc ) systems possess intense absorption bands and exhibit photoluminescence from the excited states .
3-1	17-26	Optically	substance[3]	new[3]	coref	16-18[0_3]
3-2	27-33	active	substance[3]	new[3]	_	_
3-3	34-48	phthalocyanine	substance[3]	new[3]	_	_
3-4	49-50	(	_	_	_	_
3-5	51-53	Pc	object	new	_	_
3-6	54-55	)	_	_	_	_
3-7	56-63	systems	object	new	coref	21-6[106_0]
3-8	64-71	possess	_	_	_	_
3-9	72-79	intense	abstract[7]	new[7]	_	_
3-10	80-90	absorption	abstract|abstract[7]	new|new[7]	_	_
3-11	91-96	bands	abstract[7]	new[7]	_	_
3-12	97-100	and	_	_	_	_
3-13	101-108	exhibit	abstract[8]	new[8]	_	_
3-14	109-126	photoluminescence	abstract[8]	new[8]	_	_
3-15	127-131	from	_	_	_	_
3-16	132-135	the	abstract[9]	new[9]	ana	4-1[0_9]
3-17	136-143	excited	abstract[9]	new[9]	_	_
3-18	144-150	states	abstract[9]	new[9]	_	_
3-19	151-152	.	_	_	_	_

#Text=They are also very stable and resistant to chemical , thermal , or photochemical degradation .
4-1	153-157	They	abstract	giv	ana	5-8
4-2	158-161	are	_	_	_	_
4-3	162-166	also	_	_	_	_
4-4	167-171	very	_	_	_	_
4-5	172-178	stable	_	_	_	_
4-6	179-182	and	_	_	_	_
4-7	183-192	resistant	_	_	_	_
4-8	193-195	to	_	_	_	_
4-9	196-204	chemical	abstract[11]	new[11]	_	_
4-10	205-206	,	abstract[11]	new[11]	_	_
4-11	207-214	thermal	abstract[11]	new[11]	_	_
4-12	215-216	,	abstract[11]	new[11]	_	_
4-13	217-219	or	abstract[11]	new[11]	_	_
4-14	220-233	photochemical	abstract[11]	new[11]	_	_
4-15	234-245	degradation	abstract[11]	new[11]	_	_
4-16	246-247	.	_	_	_	_

#Text=Moreover , it is particularly interesting that they act as effective photosensitizers .
5-1	248-256	Moreover	_	_	_	_
5-2	257-258	,	_	_	_	_
5-3	259-261	it	abstract	new	cata	5-3[0_14]
5-4	262-264	is	_	_	_	_
5-5	265-277	particularly	_	_	_	_
5-6	278-289	interesting	_	_	_	_
5-7	290-294	that	abstract[14]	new[14]	_	_
5-8	295-299	they	abstract|abstract[14]	giv|new[14]	ana	6-2
5-9	300-303	act	abstract[14]	new[14]	_	_
5-10	304-306	as	_	_	_	_
5-11	307-316	effective	_	_	_	_
5-12	317-333	photosensitizers	_	_	_	_
5-13	334-335	.	_	_	_	_

#Text=Following their irradiation , singlet oxygen is generated , which is used in photodynamic therapy ( PDT ) to kill selected cells .
6-1	336-345	Following	_	_	_	_
6-2	346-351	their	abstract|abstract[16]	giv|new[16]	coref|coref	25-6[0_16]|25-6[0_16]
6-3	352-363	irradiation	abstract[16]	new[16]	_	_
6-4	364-365	,	_	_	_	_
6-5	366-373	singlet	substance[17]	new[17]	coref	13-21[0_17]
6-6	374-380	oxygen	substance[17]	new[17]	_	_
6-7	381-383	is	_	_	_	_
6-8	384-393	generated	_	_	_	_
6-9	394-395	,	_	_	_	_
6-10	396-401	which	_	_	_	_
6-11	402-404	is	_	_	_	_
6-12	405-409	used	_	_	_	_
6-13	410-412	in	_	_	_	_
6-14	413-425	photodynamic	abstract|abstract[19]	new|new[19]	appos|appos	6-17[0_19]|6-17[0_19]
6-15	426-433	therapy	abstract[19]	new[19]	_	_
6-16	434-435	(	_	_	_	_
6-17	436-439	PDT	abstract	giv	coref	23-20[134_0]
6-18	440-441	)	_	_	_	_
6-19	442-444	to	_	_	_	_
6-20	445-449	kill	_	_	_	_
6-21	450-458	selected	object[21]	new[21]	coref	7-10[23_21]
6-22	459-464	cells	object[21]	new[21]	_	_
6-23	465-466	.	_	_	_	_

#Text=This kind of activity can also be used against microbial cells .
7-1	467-471	This	_	_	_	_
7-2	472-476	kind	_	_	_	_
7-3	477-479	of	_	_	_	_
7-4	480-488	activity	_	_	_	_
7-5	489-492	can	_	_	_	_
7-6	493-497	also	_	_	_	_
7-7	498-500	be	_	_	_	_
7-8	501-505	used	_	_	_	_
7-9	506-513	against	_	_	_	_
7-10	514-523	microbial	object|object[23]	new|giv[23]	_	_
7-11	524-529	cells	object[23]	giv[23]	_	_
7-12	530-531	.	_	_	_	_

#Text=For example , Nyamu et al. reviewed antibacterial efficacy of phthalocyanines and noticed that Gram-positive bacteria are more sensitive to phthalocyanines than Gram-negative bacteria .
8-1	532-535	For	_	_	_	_
8-2	536-543	example	_	_	_	_
8-3	544-545	,	_	_	_	_
8-4	546-551	Nyamu	person	new	_	_
8-5	552-554	et	_	_	_	_
8-6	555-558	al.	_	_	_	_
8-7	559-567	reviewed	_	_	_	_
8-8	568-581	antibacterial	abstract[25]	new[25]	ana	9-1[0_25]
8-9	582-590	efficacy	abstract[25]	new[25]	_	_
8-10	591-593	of	abstract[25]	new[25]	_	_
8-11	594-609	phthalocyanines	abstract[25]|substance	new[25]|new	coref	8-21[28_0]
8-12	610-613	and	_	_	_	_
8-13	614-621	noticed	_	_	_	_
8-14	622-626	that	_	_	_	_
8-15	627-640	Gram-positive	animal[27]	new[27]	coref	8-23[29_27]
8-16	641-649	bacteria	animal[27]	new[27]	_	_
8-17	650-653	are	_	_	_	_
8-18	654-658	more	_	_	_	_
8-19	659-668	sensitive	_	_	_	_
8-20	669-671	to	_	_	_	_
8-21	672-687	phthalocyanines	substance[28]	giv[28]	coref	14-5[0_28]
8-22	688-692	than	substance[28]	giv[28]	_	_
8-23	693-706	Gram-negative	substance[28]|animal[29]	giv[28]|giv[29]	coref	15-6[0_29]
8-24	707-715	bacteria	substance[28]|animal[29]	giv[28]|giv[29]	_	_
8-25	716-717	.	_	_	_	_

#Text=This may be a result of differences in the cell structure .
9-1	718-722	This	abstract	giv	_	_
9-2	723-726	may	_	_	_	_
9-3	727-729	be	_	_	_	_
9-4	730-731	a	_	_	_	_
9-5	732-738	result	_	_	_	_
9-6	739-741	of	_	_	_	_
9-7	742-753	differences	abstract[31]	new[31]	ana	10-12[0_31]
9-8	754-756	in	abstract[31]	new[31]	_	_
9-9	757-760	the	abstract[31]|abstract[33]	new[31]|new[33]	coref	12-27[0_33]
9-10	761-765	cell	abstract[31]|object|abstract[33]	new[31]|new|new[33]	coref	12-4[49_0]
9-11	766-775	structure	abstract[31]|abstract[33]	new[31]|new[33]	_	_
9-12	776-777	.	_	_	_	_

#Text=In general , the outer membrane present in Gram-negative species makes them more resistant .
10-1	778-780	In	_	_	_	_
10-2	781-788	general	abstract	new	ana	11-3
10-3	789-790	,	_	_	_	_
10-4	791-794	the	_	_	_	_
10-5	795-800	outer	_	_	_	_
10-6	801-809	membrane	substance	new	coref	13-13[64_0]
10-7	810-817	present	_	_	_	_
10-8	818-820	in	_	_	_	_
10-9	821-834	Gram-negative	animal|abstract[37]	new|new[37]	coref|coref|coref|coref	13-21[66_37]|16-23|13-21[66_37]|16-23
10-10	835-842	species	abstract[37]	new[37]	_	_
10-11	843-848	makes	_	_	_	_
10-12	849-853	them	abstract	giv	_	_
10-13	854-858	more	_	_	_	_
10-14	859-868	resistant	_	_	_	_
10-15	869-870	.	_	_	_	_

#Text=However , it is difficult to explain this phenomenon in detail without deeper understanding of the interactions , and it is impossible to generalize the antibacterial mechanism of the compounds .
11-1	871-878	However	_	_	_	_
11-2	879-880	,	_	_	_	_
11-3	881-883	it	abstract	giv	ana	11-20
11-4	884-886	is	_	_	_	_
11-5	887-896	difficult	_	_	_	_
11-6	897-899	to	person[40]	new[40]	_	_
11-7	900-907	explain	person[40]	new[40]	_	_
11-8	908-912	this	person[40]|abstract[41]	new[40]|new[41]	_	_
11-9	913-923	phenomenon	person[40]|abstract[41]	new[40]|new[41]	_	_
11-10	924-926	in	person[40]|abstract[41]	new[40]|new[41]	_	_
11-11	927-933	detail	person[40]|abstract[41]	new[40]|new[41]	_	_
11-12	934-941	without	_	_	_	_
11-13	942-948	deeper	abstract[42]	new[42]	_	_
11-14	949-962	understanding	abstract[42]	new[42]	_	_
11-15	963-965	of	abstract[42]	new[42]	_	_
11-16	966-969	the	abstract[42]|abstract[43]	new[42]|new[43]	_	_
11-17	970-982	interactions	abstract[42]|abstract[43]	new[42]|new[43]	_	_
11-18	983-984	,	_	_	_	_
11-19	985-988	and	_	_	_	_
11-20	989-991	it	abstract	giv	_	_
11-21	992-994	is	_	_	_	_
11-22	995-1005	impossible	_	_	_	_
11-23	1006-1008	to	_	_	_	_
11-24	1009-1019	generalize	_	_	_	_
11-25	1020-1023	the	abstract[45]	new[45]	_	_
11-26	1024-1037	antibacterial	abstract[45]	new[45]	_	_
11-27	1038-1047	mechanism	abstract[45]	new[45]	_	_
11-28	1048-1050	of	abstract[45]	new[45]	_	_
11-29	1051-1054	the	abstract[45]|substance[46]	new[45]|new[46]	coref	13-10[62_46]
11-30	1055-1064	compounds	abstract[45]|substance[46]	new[45]|new[46]	_	_
11-31	1065-1066	.	_	_	_	_

#Text=The interaction with bacterial cell and the cell ’s response strongly depends on the physicochemical properties of the materials ( such as size , shape , structure , charge , etc. ) , as we have previously described .
12-1	1067-1070	The	event[47]	new[47]	_	_
12-2	1071-1082	interaction	event[47]	new[47]	_	_
12-3	1083-1087	with	event[47]	new[47]	_	_
12-4	1088-1097	bacterial	event[47]|substance|object[49]	new[47]|new|giv[49]	coref|coref|coref|coref	12-8[50_49]|13-13|12-8[50_49]|13-13
12-5	1098-1102	cell	event[47]|object[49]	new[47]|giv[49]	_	_
12-6	1103-1106	and	event[47]	new[47]	_	_
12-7	1107-1110	the	event[47]|abstract[51]	new[47]|new[51]	_	_
12-8	1111-1115	cell	event[47]|object[50]|abstract[51]	new[47]|giv[50]|new[51]	coref	14-12[0_50]
12-9	1116-1118	’s	event[47]|object[50]|abstract[51]	new[47]|giv[50]|new[51]	_	_
12-10	1119-1127	response	event[47]|abstract[51]	new[47]|new[51]	_	_
12-11	1128-1136	strongly	_	_	_	_
12-12	1137-1144	depends	_	_	_	_
12-13	1145-1147	on	_	_	_	_
12-14	1148-1151	the	abstract[52]	new[52]	_	_
12-15	1152-1167	physicochemical	abstract[52]	new[52]	_	_
12-16	1168-1178	properties	abstract[52]	new[52]	_	_
12-17	1179-1181	of	abstract[52]	new[52]	_	_
12-18	1182-1185	the	abstract[52]|substance[53]	new[52]|new[53]	coref	19-11[0_53]
12-19	1186-1195	materials	abstract[52]|substance[53]	new[52]|new[53]	_	_
12-20	1196-1197	(	abstract[52]	new[52]	_	_
12-21	1198-1202	such	abstract[52]	new[52]	_	_
12-22	1203-1205	as	abstract[52]	new[52]	_	_
12-23	1206-1210	size	abstract[52]|abstract	new[52]|new	_	_
12-24	1211-1212	,	abstract[52]	new[52]	_	_
12-25	1213-1218	shape	abstract[52]|abstract	new[52]|new	_	_
12-26	1219-1220	,	abstract[52]	new[52]	_	_
12-27	1221-1230	structure	abstract[52]|abstract	new[52]|giv	_	_
12-28	1231-1232	,	abstract[52]	new[52]	_	_
12-29	1233-1239	charge	abstract[52]|abstract	new[52]|new	_	_
12-30	1240-1241	,	abstract[52]	new[52]	_	_
12-31	1242-1246	etc.	abstract[52]	new[52]	_	_
12-32	1247-1248	)	abstract[52]	new[52]	_	_
12-33	1249-1250	,	_	_	_	_
12-34	1251-1253	as	_	_	_	_
12-35	1254-1256	we	person	acc	ana	22-2
12-36	1257-1261	have	_	_	_	_
12-37	1262-1272	previously	_	_	_	_
12-38	1273-1282	described	_	_	_	_
12-39	1283-1284	.	_	_	_	_

#Text=One of the possible antibacterial mechanisms is interaction of the compounds with bacterial membrane , while the other is reactive oxygen species production .
13-1	1285-1288	One	abstract[59]	new[59]	coref	13-8[61_59]
13-2	1289-1291	of	abstract[59]	new[59]	_	_
13-3	1292-1295	the	abstract[59]|abstract[60]	new[59]|new[60]	_	_
13-4	1296-1304	possible	abstract[59]|abstract[60]	new[59]|new[60]	_	_
13-5	1305-1318	antibacterial	abstract[59]|abstract[60]	new[59]|new[60]	_	_
13-6	1319-1329	mechanisms	abstract[59]|abstract[60]	new[59]|new[60]	_	_
13-7	1330-1332	is	_	_	_	_
13-8	1333-1344	interaction	abstract[61]	giv[61]	_	_
13-9	1345-1347	of	abstract[61]	giv[61]	_	_
13-10	1348-1351	the	abstract[61]|substance[62]	giv[61]|giv[62]	_	_
13-11	1352-1361	compounds	abstract[61]|substance[62]	giv[61]|giv[62]	_	_
13-12	1362-1366	with	abstract[61]|substance[62]	giv[61]|giv[62]	_	_
13-13	1367-1376	bacterial	abstract[61]|substance[62]|animal|substance[64]	giv[61]|giv[62]|giv|giv[64]	_	_
13-14	1377-1385	membrane	abstract[61]|substance[62]|substance[64]	giv[61]|giv[62]|giv[64]	_	_
13-15	1386-1387	,	_	_	_	_
13-16	1388-1393	while	_	_	_	_
13-17	1394-1397	the	_	_	_	_
13-18	1398-1403	other	_	_	_	_
13-19	1404-1406	is	_	_	_	_
13-20	1407-1415	reactive	abstract[67]	new[67]	_	_
13-21	1416-1422	oxygen	substance|abstract[66]|abstract[67]	giv|giv[66]|new[67]	coref|coref	27-12|27-12
13-22	1423-1430	species	abstract[66]|abstract[67]	giv[66]|new[67]	_	_
13-23	1431-1441	production	abstract[67]	new[67]	_	_
13-24	1442-1443	.	_	_	_	_

#Text=In the case of phthalocyanines , Mikula et al. underlined that cell binding is a key factor influencing their antibacterial activity .
14-1	1444-1446	In	_	_	_	_
14-2	1447-1450	the	abstract[68]	new[68]	_	_
14-3	1451-1455	case	abstract[68]	new[68]	_	_
14-4	1456-1458	of	abstract[68]	new[68]	_	_
14-5	1459-1474	phthalocyanines	abstract[68]|substance	new[68]|giv	ana	14-19
14-6	1475-1476	,	_	_	_	_
14-7	1477-1483	Mikula	person	new	_	_
14-8	1484-1486	et	_	_	_	_
14-9	1487-1490	al.	_	_	_	_
14-10	1491-1501	underlined	_	_	_	_
14-11	1502-1506	that	_	_	_	_
14-12	1507-1511	cell	object|abstract[72]	giv|new[72]	coref|coref	14-15[73_72]|14-15[73_72]
14-13	1512-1519	binding	abstract[72]	new[72]	_	_
14-14	1520-1522	is	_	_	_	_
14-15	1523-1524	a	abstract[73]	giv[73]	_	_
14-16	1525-1528	key	abstract[73]	giv[73]	_	_
14-17	1529-1535	factor	abstract[73]	giv[73]	_	_
14-18	1536-1547	influencing	_	_	_	_
14-19	1548-1553	their	substance|abstract[75]	giv|new[75]	coref|coref|coref|coref	15-10[78_0]|16-14[83_75]|15-10[78_0]|16-14[83_75]
14-20	1554-1567	antibacterial	abstract[75]	new[75]	_	_
14-21	1568-1576	activity	abstract[75]	new[75]	_	_
14-22	1577-1578	.	_	_	_	_

#Text=Thus , the susceptibility of bacteria depends on the kind of phthalocyanines .
15-1	1579-1583	Thus	_	_	_	_
15-2	1584-1585	,	_	_	_	_
15-3	1586-1589	the	abstract[76]	new[76]	_	_
15-4	1590-1604	susceptibility	abstract[76]	new[76]	_	_
15-5	1605-1607	of	abstract[76]	new[76]	_	_
15-6	1608-1616	bacteria	abstract[76]|animal	new[76]|giv	coref	16-23[87_0]
15-7	1617-1624	depends	_	_	_	_
15-8	1625-1627	on	_	_	_	_
15-9	1628-1631	the	_	_	_	_
15-10	1632-1636	kind	substance[78]	giv[78]	coref	16-9[0_78]
15-11	1637-1639	of	substance[78]	giv[78]	_	_
15-12	1640-1655	phthalocyanines	substance[78]	giv[78]	_	_
15-13	1656-1657	.	_	_	_	_

#Text=De Silva et al. indicated that conjugation of phthalocyanines with antibiotics also enhances the antibacterial activity of phthalocyanine – sulfonamides conjugate against Gram-negative bacteria .
16-1	1658-1660	De	person[79]	new[79]	_	_
16-2	1661-1666	Silva	person[79]	new[79]	_	_
16-3	1667-1669	et	_	_	_	_
16-4	1670-1673	al.	_	_	_	_
16-5	1674-1683	indicated	_	_	_	_
16-6	1684-1688	that	abstract[80]	new[80]	_	_
16-7	1689-1700	conjugation	abstract[80]	new[80]	_	_
16-8	1701-1703	of	abstract[80]	new[80]	_	_
16-9	1704-1719	phthalocyanines	abstract[80]|substance	new[80]|giv	coref	20-1
16-10	1720-1724	with	_	_	_	_
16-11	1725-1736	antibiotics	substance	new	_	_
16-12	1737-1741	also	_	_	_	_
16-13	1742-1750	enhances	_	_	_	_
16-14	1751-1754	the	abstract[83]	giv[83]	coref	18-9[95_83]
16-15	1755-1768	antibacterial	abstract[83]	giv[83]	_	_
16-16	1769-1777	activity	abstract[83]	giv[83]	_	_
16-17	1778-1780	of	abstract[83]	giv[83]	_	_
16-18	1781-1795	phthalocyanine	abstract[83]|substance	giv[83]|giv	appos	16-20
16-19	1796-1797	–	_	_	_	_
16-20	1798-1810	sulfonamides	substance	giv	ana	18-9
16-21	1811-1820	conjugate	_	_	_	_
16-22	1821-1828	against	_	_	_	_
16-23	1829-1842	Gram-negative	abstract|animal[87]	giv|giv[87]	coref|coref	22-30[0_87]|22-30[0_87]
16-24	1843-1851	bacteria	animal[87]	giv[87]	_	_
16-25	1852-1853	.	_	_	_	_

#Text=In general , many articles about the antibacterial properties of Pcs as photosensitizers have already been published .
17-1	1854-1856	In	_	_	_	_
17-2	1857-1864	general	abstract[88]	new[88]	_	_
17-3	1865-1866	,	abstract[88]	new[88]	_	_
17-4	1867-1871	many	abstract[88]	new[88]	_	_
17-5	1872-1880	articles	abstract[88]	new[88]	_	_
17-6	1881-1886	about	abstract[88]	new[88]	_	_
17-7	1887-1890	the	abstract[88]|abstract[89]	new[88]|new[89]	coref	21-14[107_89]
17-8	1891-1904	antibacterial	abstract[88]|abstract[89]	new[88]|new[89]	_	_
17-9	1905-1915	properties	abstract[88]|abstract[89]	new[88]|new[89]	_	_
17-10	1916-1918	of	abstract[88]|abstract[89]	new[88]|new[89]	_	_
17-11	1919-1922	Pcs	abstract[88]|abstract[89]|object	new[88]|new[89]|new	_	_
17-12	1923-1925	as	_	_	_	_
17-13	1926-1942	photosensitizers	substance	new	_	_
17-14	1943-1947	have	_	_	_	_
17-15	1948-1955	already	_	_	_	_
17-16	1956-1960	been	_	_	_	_
17-17	1961-1970	published	_	_	_	_
17-18	1971-1972	.	_	_	_	_

#Text=However , there is lack of reports on their activity against multi-drug-resistant microorganisms .
18-1	1973-1980	However	_	_	_	_
18-2	1981-1982	,	_	_	_	_
18-3	1983-1988	there	_	_	_	_
18-4	1989-1991	is	_	_	_	_
18-5	1992-1996	lack	abstract[92]	new[92]	_	_
18-6	1997-1999	of	abstract[92]	new[92]	_	_
18-7	2000-2007	reports	abstract[92]|abstract[93]	new[92]|new[93]	_	_
18-8	2008-2010	on	abstract[92]|abstract[93]	new[92]|new[93]	_	_
18-9	2011-2016	their	abstract[92]|abstract[93]|substance|abstract[95]	new[92]|new[93]|giv|giv[95]	_	_
18-10	2017-2025	activity	abstract[92]|abstract[93]|abstract[95]	new[92]|new[93]|giv[95]	_	_
18-11	2026-2033	against	abstract[92]|abstract[93]|abstract[95]	new[92]|new[93]|giv[95]	_	_
18-12	2034-2054	multi-drug-resistant	abstract[92]|abstract[93]|abstract[95]|substance[96]	new[92]|new[93]|giv[95]|new[96]	_	_
18-13	2055-2069	microorganisms	abstract[92]|abstract[93]|abstract[95]|substance[96]	new[92]|new[93]|giv[95]|new[96]	_	_
18-14	2070-2071	.	_	_	_	_

#Text=Various carbon-based composites are fabricated to enhance the activity of materials , for example , in photocatalysis .
19-1	2072-2079	Various	object[97]	new[97]	_	_
19-2	2080-2092	carbon-based	object[97]	new[97]	_	_
19-3	2093-2103	composites	object[97]	new[97]	_	_
19-4	2104-2107	are	_	_	_	_
19-5	2108-2118	fabricated	_	_	_	_
19-6	2119-2121	to	_	_	_	_
19-7	2122-2129	enhance	_	_	_	_
19-8	2130-2133	the	abstract[98]	new[98]	_	_
19-9	2134-2142	activity	abstract[98]	new[98]	_	_
19-10	2143-2145	of	abstract[98]	new[98]	_	_
19-11	2146-2155	materials	abstract[98]|substance	new[98]|giv	coref	25-12[150_0]
19-12	2156-2157	,	_	_	_	_
19-13	2158-2161	for	_	_	_	_
19-14	2162-2169	example	_	_	_	_
19-15	2170-2171	,	_	_	_	_
19-16	2172-2174	in	_	_	_	_
19-17	2175-2189	photocatalysis	abstract	new	_	_
19-18	2190-2191	.	_	_	_	_

#Text=Phthalocyanines have also been incorporated into graphene or other carbon structures for photocatalytic or optoelectronic applications .
20-1	2192-2207	Phthalocyanines	substance	giv	coref	22-21
20-2	2208-2212	have	_	_	_	_
20-3	2213-2217	also	_	_	_	_
20-4	2218-2222	been	_	_	_	_
20-5	2223-2235	incorporated	_	_	_	_
20-6	2236-2240	into	_	_	_	_
20-7	2241-2249	graphene	substance	new	_	_
20-8	2250-2252	or	_	_	_	_
20-9	2253-2258	other	abstract[104]	new[104]	_	_
20-10	2259-2265	carbon	substance|abstract[104]	new|new[104]	_	_
20-11	2266-2276	structures	abstract[104]	new[104]	_	_
20-12	2277-2280	for	abstract[104]	new[104]	_	_
20-13	2281-2295	photocatalytic	abstract[104]|abstract[105]	new[104]|new[105]	_	_
20-14	2296-2298	or	abstract[104]|abstract[105]	new[104]|new[105]	_	_
20-15	2299-2313	optoelectronic	abstract[104]|abstract[105]	new[104]|new[105]	_	_
20-16	2314-2326	applications	abstract[104]|abstract[105]	new[104]|new[105]	_	_
20-17	2327-2328	.	_	_	_	_

#Text=On the other hand , specific graphene-based systems have been found to possess good antimicrobial properties .
21-1	2329-2331	On	_	_	_	_
21-2	2332-2335	the	_	_	_	_
21-3	2336-2341	other	_	_	_	_
21-4	2342-2346	hand	_	_	_	_
21-5	2347-2348	,	_	_	_	_
21-6	2349-2357	specific	object[106]	giv[106]	coref	27-4[175_106]
21-7	2358-2372	graphene-based	object[106]	giv[106]	_	_
21-8	2373-2380	systems	object[106]	giv[106]	_	_
21-9	2381-2385	have	_	_	_	_
21-10	2386-2390	been	_	_	_	_
21-11	2391-2396	found	_	_	_	_
21-12	2397-2399	to	_	_	_	_
21-13	2400-2407	possess	_	_	_	_
21-14	2408-2412	good	abstract[107]	giv[107]	_	_
21-15	2413-2426	antimicrobial	abstract[107]	giv[107]	_	_
21-16	2427-2437	properties	abstract[107]	giv[107]	_	_
21-17	2438-2439	.	_	_	_	_

#Text=In our study , we wanted to combine antimicrobial effects caused by two different factors — graphite oxide flakes and phthalocyanines activated by light — and use them against bacteria causing infection of the root canals of teeth .
22-1	2440-2442	In	_	_	_	_
22-2	2443-2446	our	person|abstract[109]	giv|new[109]	ana|ana	22-5|22-5
22-3	2447-2452	study	abstract[109]	new[109]	_	_
22-4	2453-2454	,	_	_	_	_
22-5	2455-2457	we	person	giv	ana	23-27
22-6	2458-2464	wanted	_	_	_	_
22-7	2465-2467	to	_	_	_	_
22-8	2468-2475	combine	_	_	_	_
22-9	2476-2489	antimicrobial	abstract[111]	new[111]	_	_
22-10	2490-2497	effects	abstract[111]	new[111]	_	_
22-11	2498-2504	caused	_	_	_	_
22-12	2505-2507	by	_	_	_	_
22-13	2508-2511	two	abstract[112]|abstract[113]	new[112]|new[113]	ana|ana	22-28[0_113]|22-28[0_113]
22-14	2512-2521	different	abstract[112]|abstract[113]	new[112]|new[113]	_	_
22-15	2522-2529	factors	abstract[112]|abstract[113]	new[112]|new[113]	_	_
22-16	2530-2531	—	abstract[113]	new[113]	_	_
22-17	2532-2540	graphite	abstract[113]|abstract|substance[116]	new[113]|new|new[116]	coref|coref|coref|coref	23-16|26-38[173_116]|23-16|26-38[173_116]
22-18	2541-2546	oxide	abstract[113]|substance|substance[116]	new[113]|new|new[116]	coref	26-39
22-19	2547-2553	flakes	abstract[113]|substance[116]	new[113]|new[116]	_	_
22-20	2554-2557	and	abstract[113]	new[113]	_	_
22-21	2558-2573	phthalocyanines	abstract[113]|substance	new[113]|giv	coref	26-9[164_0]
22-22	2574-2583	activated	_	_	_	_
22-23	2584-2586	by	_	_	_	_
22-24	2587-2592	light	abstract	new	coref	27-18
22-25	2593-2594	—	_	_	_	_
22-26	2595-2598	and	_	_	_	_
22-27	2599-2602	use	_	_	_	_
22-28	2603-2607	them	abstract	giv	_	_
22-29	2608-2615	against	_	_	_	_
22-30	2616-2624	bacteria	animal	giv	coref	24-11[144_0]
22-31	2625-2632	causing	_	_	_	_
22-32	2633-2642	infection	abstract[121]	new[121]	_	_
22-33	2643-2645	of	abstract[121]	new[121]	_	_
22-34	2646-2649	the	abstract[121]|object[123]	new[121]|new[123]	_	_
22-35	2650-2654	root	abstract[121]|plant|object[123]	new[121]|new|new[123]	_	_
22-36	2655-2661	canals	abstract[121]|object[123]	new[121]|new[123]	_	_
22-37	2662-2664	of	abstract[121]|object[123]	new[121]|new[123]	_	_
22-38	2665-2670	teeth	abstract[121]|object[123]|object	new[121]|new[123]|new	_	_
22-39	2671-2672	.	_	_	_	_

#Text=The application of ZrPc/GO-based composite ( ZrPc with lysine ligand , LYS ; GO , graphite oxide ) for antibacterial PDT has already been shown by us , where the action against Staphylococcus aureus ATCC 6538 , Pseudomonas aeruginosa ATCC 27853 , and Escherichia coli ( E. coli ) ATCC 11229 was proven .
23-1	2673-2676	The	abstract[125]	new[125]	_	_
23-2	2677-2688	application	abstract[125]	new[125]	_	_
23-3	2689-2691	of	abstract[125]	new[125]	_	_
23-4	2692-2705	ZrPc/GO-based	abstract[125]|abstract|object[127]	new[125]|new|new[127]	_	_
23-5	2706-2715	composite	abstract[125]|object[127]	new[125]|new[127]	_	_
23-6	2716-2717	(	_	_	_	_
23-7	2718-2722	ZrPc	substance[128]	new[128]	_	_
23-8	2723-2727	with	substance[128]	new[128]	_	_
23-9	2728-2734	lysine	substance[128]|abstract|substance[130]	new[128]|new|new[130]	_	_
23-10	2735-2741	ligand	substance[128]|substance[130]	new[128]|new[130]	_	_
23-11	2742-2743	,	substance[128]	new[128]	_	_
23-12	2744-2747	LYS	substance[128]|substance	new[128]|new	_	_
23-13	2748-2749	;	_	_	_	_
23-14	2750-2752	GO	_	_	_	_
23-15	2753-2754	,	_	_	_	_
23-16	2755-2763	graphite	abstract	giv	coref	26-38
23-17	2764-2769	oxide	_	_	_	_
23-18	2770-2771	)	_	_	_	_
23-19	2772-2775	for	_	_	_	_
23-20	2776-2789	antibacterial	substance|abstract[134]	new|giv[134]	_	_
23-21	2790-2793	PDT	abstract[134]	giv[134]	_	_
23-22	2794-2797	has	_	_	_	_
23-23	2798-2805	already	_	_	_	_
23-24	2806-2810	been	_	_	_	_
23-25	2811-2816	shown	_	_	_	_
23-26	2817-2819	by	_	_	_	_
23-27	2820-2822	us	person	giv	_	_
23-28	2823-2824	,	_	_	_	_
23-29	2825-2830	where	_	_	_	_
23-30	2831-2834	the	abstract[136]	new[136]	_	_
23-31	2835-2841	action	abstract[136]	new[136]	_	_
23-32	2842-2849	against	abstract[136]	new[136]	_	_
23-33	2850-2864	Staphylococcus	abstract[136]|abstract	new[136]|new	_	_
23-34	2865-2871	aureus	abstract[136]	new[136]	_	_
23-35	2872-2876	ATCC	abstract[136]	new[136]	_	_
23-36	2877-2881	6538	abstract[136]	new[136]	_	_
23-37	2882-2883	,	_	_	_	_
23-38	2884-2895	Pseudomonas	_	_	_	_
23-39	2896-2906	aeruginosa	_	_	_	_
23-40	2907-2911	ATCC	abstract	new	_	_
23-41	2912-2917	27853	_	_	_	_
23-42	2918-2919	,	_	_	_	_
23-43	2920-2923	and	_	_	_	_
23-44	2924-2935	Escherichia	abstract	new	_	_
23-45	2936-2940	coli	_	_	_	_
23-46	2941-2942	(	_	_	_	_
23-47	2943-2945	E.	_	_	_	_
23-48	2946-2950	coli	_	_	_	_
23-49	2951-2952	)	_	_	_	_
23-50	2953-2957	ATCC	abstract[140]	new[140]	ana	24-7[0_140]
23-51	2958-2963	11229	abstract[140]	new[140]	_	_
23-52	2964-2967	was	_	_	_	_
23-53	2968-2974	proven	_	_	_	_
23-54	2975-2976	.	_	_	_	_

#Text=In agreement with other studies , it was indicated that Gram-positive bacteria are more sensitive strains .
24-1	2977-2979	In	_	_	_	_
24-2	2980-2989	agreement	event[141]	new[141]	_	_
24-3	2990-2994	with	event[141]	new[141]	_	_
24-4	2995-3000	other	event[141]|abstract[142]	new[141]|new[142]	_	_
24-5	3001-3008	studies	event[141]|abstract[142]	new[141]|new[142]	_	_
24-6	3009-3010	,	_	_	_	_
24-7	3011-3013	it	abstract	giv	_	_
24-8	3014-3017	was	_	_	_	_
24-9	3018-3027	indicated	_	_	_	_
24-10	3028-3032	that	_	_	_	_
24-11	3033-3046	Gram-positive	abstract[144]	giv[144]	coref	24-14[145_144]
24-12	3047-3055	bacteria	abstract[144]	giv[144]	_	_
24-13	3056-3059	are	_	_	_	_
24-14	3060-3064	more	abstract[145]	giv[145]	coref	28-5[183_145]
24-15	3065-3074	sensitive	abstract[145]	giv[145]	_	_
24-16	3075-3082	strains	abstract[145]	giv[145]	_	_
24-17	3083-3084	.	_	_	_	_

#Text=However , the influence of irradiation on enhanced antimicrobial activity of bis(LYS)ZrPc/GO materials was observed , particularly in the case of P. aeruginosa ( a multidrug resistant pathogen ) , where minimal inhibitory concentration ( MIC ) was equal to 0.32 mg/mL in comparison to 40 mg/mL needed for the nonirradiated sample .
25-1	3085-3092	However	_	_	_	_
25-2	3093-3094	,	_	_	_	_
25-3	3095-3098	the	abstract[146]	new[146]	_	_
25-4	3099-3108	influence	abstract[146]	new[146]	_	_
25-5	3109-3111	of	abstract[146]	new[146]	_	_
25-6	3112-3123	irradiation	abstract[146]|abstract	new[146]|giv	_	_
25-7	3124-3126	on	abstract[146]	new[146]	_	_
25-8	3127-3135	enhanced	abstract[146]|abstract[148]	new[146]|new[148]	_	_
25-9	3136-3149	antimicrobial	abstract[146]|abstract[148]	new[146]|new[148]	_	_
25-10	3150-3158	activity	abstract[146]|abstract[148]	new[146]|new[148]	_	_
25-11	3159-3161	of	abstract[146]|abstract[148]	new[146]|new[148]	_	_
25-12	3162-3177	bis(LYS)ZrPc/GO	abstract[146]|abstract[148]|place|substance[150]	new[146]|new[148]|new|giv[150]	coref|coref	26-34[170_150]|26-34[170_150]
25-13	3178-3187	materials	abstract[146]|abstract[148]|substance[150]	new[146]|new[148]|giv[150]	_	_
25-14	3188-3191	was	_	_	_	_
25-15	3192-3200	observed	_	_	_	_
25-16	3201-3202	,	_	_	_	_
25-17	3203-3215	particularly	abstract[151]	new[151]	_	_
25-18	3216-3218	in	abstract[151]	new[151]	_	_
25-19	3219-3222	the	abstract[151]	new[151]	_	_
25-20	3223-3227	case	abstract[151]	new[151]	_	_
25-21	3228-3230	of	abstract[151]	new[151]	_	_
25-22	3231-3233	P.	abstract[151]|place	new[151]|new	_	_
25-23	3234-3244	aeruginosa	abstract[151]	new[151]	_	_
25-24	3245-3246	(	_	_	_	_
25-25	3247-3248	a	_	_	_	_
25-26	3249-3258	multidrug	_	_	_	_
25-27	3259-3268	resistant	object[153]	new[153]	_	_
25-28	3269-3277	pathogen	object[153]	new[153]	_	_
25-29	3278-3279	)	_	_	_	_
25-30	3280-3281	,	_	_	_	_
25-31	3282-3287	where	_	_	_	_
25-32	3288-3295	minimal	abstract[155]	new[155]	_	_
25-33	3296-3306	inhibitory	abstract|abstract[155]	new|new[155]	_	_
25-34	3307-3320	concentration	abstract[155]	new[155]	_	_
25-35	3321-3322	(	_	_	_	_
25-36	3323-3326	MIC	object	new	_	_
25-37	3327-3328	)	_	_	_	_
25-38	3329-3332	was	_	_	_	_
25-39	3333-3338	equal	_	_	_	_
25-40	3339-3341	to	_	_	_	_
25-41	3342-3346	0.32	quantity[157]	new[157]	_	_
25-42	3347-3352	mg/mL	quantity[157]	new[157]	_	_
25-43	3353-3355	in	_	_	_	_
25-44	3356-3366	comparison	abstract[158]	new[158]	_	_
25-45	3367-3369	to	abstract[158]	new[158]	_	_
25-46	3370-3372	40	abstract[158]|quantity[159]	new[158]|new[159]	_	_
25-47	3373-3378	mg/mL	abstract[158]|quantity[159]	new[158]|new[159]	_	_
25-48	3379-3385	needed	_	_	_	_
25-49	3386-3389	for	_	_	_	_
25-50	3390-3393	the	object[160]	new[160]	_	_
25-51	3394-3407	nonirradiated	object[160]	new[160]	_	_
25-52	3408-3414	sample	object[160]	new[160]	_	_
25-53	3415-3416	.	_	_	_	_

#Text=The aim of this paper was to characterize two synthesized zirconium(IV ) phthalocyanines , axially substituted with different ligands ( hydrocarbon chains terminated with amino groups ) , which were used to obtain two hybrid materials with graphite oxide flakes .
26-1	3417-3420	The	abstract[161]	new[161]	_	_
26-2	3421-3424	aim	abstract[161]	new[161]	_	_
26-3	3425-3427	of	abstract[161]	new[161]	_	_
26-4	3428-3432	this	abstract[161]|object[162]	new[161]|new[162]	_	_
26-5	3433-3438	paper	abstract[161]|object[162]	new[161]|new[162]	_	_
26-6	3439-3442	was	_	_	_	_
26-7	3443-3445	to	_	_	_	_
26-8	3446-3458	characterize	_	_	_	_
26-9	3459-3462	two	substance[164]	giv[164]	_	_
26-10	3463-3474	synthesized	substance[163]|substance[164]	new[163]|giv[164]	_	_
26-11	3475-3487	zirconium(IV	substance[163]|substance[164]	new[163]|giv[164]	_	_
26-12	3488-3489	)	substance[164]	giv[164]	_	_
26-13	3490-3505	phthalocyanines	substance[164]	giv[164]	_	_
26-14	3506-3507	,	_	_	_	_
26-15	3508-3515	axially	_	_	_	_
26-16	3516-3527	substituted	_	_	_	_
26-17	3528-3532	with	_	_	_	_
26-18	3533-3542	different	abstract[165]	new[165]	appos	26-21[167_165]
26-19	3543-3550	ligands	abstract[165]	new[165]	_	_
26-20	3551-3552	(	_	_	_	_
26-21	3553-3564	hydrocarbon	substance|abstract[167]	new|giv[167]	_	_
26-22	3565-3571	chains	abstract[167]	giv[167]	_	_
26-23	3572-3582	terminated	_	_	_	_
26-24	3583-3587	with	_	_	_	_
26-25	3588-3593	amino	object|substance[169]	new|new[169]	_	_
26-26	3594-3600	groups	substance[169]	new[169]	_	_
26-27	3601-3602	)	_	_	_	_
26-28	3603-3604	,	_	_	_	_
26-29	3605-3610	which	_	_	_	_
26-30	3611-3615	were	_	_	_	_
26-31	3616-3620	used	_	_	_	_
26-32	3621-3623	to	_	_	_	_
26-33	3624-3630	obtain	_	_	_	_
26-34	3631-3634	two	substance[170]	giv[170]	_	_
26-35	3635-3641	hybrid	substance[170]	giv[170]	_	_
26-36	3642-3651	materials	substance[170]	giv[170]	_	_
26-37	3652-3656	with	_	_	_	_
26-38	3657-3665	graphite	abstract|object[173]	giv|giv[173]	_	_
26-39	3666-3671	oxide	substance|object[173]	giv|giv[173]	_	_
26-40	3672-3678	flakes	object[173]	giv[173]	_	_
26-41	3679-3680	.	_	_	_	_

#Text=Optical properties of all systems were described , also showing singlet oxygen generation after red – near-infrared light exposition .
27-1	3681-3688	Optical	object[174]	new[174]	_	_
27-2	3689-3699	properties	object[174]	new[174]	_	_
27-3	3700-3702	of	object[174]	new[174]	_	_
27-4	3703-3706	all	object[174]|object[175]	new[174]|giv[175]	_	_
27-5	3707-3714	systems	object[174]|object[175]	new[174]|giv[175]	_	_
27-6	3715-3719	were	_	_	_	_
27-7	3720-3729	described	_	_	_	_
27-8	3730-3731	,	_	_	_	_
27-9	3732-3736	also	_	_	_	_
27-10	3737-3744	showing	_	_	_	_
27-11	3745-3752	singlet	object|abstract[178]	new|new[178]	_	_
27-12	3753-3759	oxygen	substance|abstract[178]	giv|new[178]	_	_
27-13	3760-3770	generation	abstract[178]	new[178]	_	_
27-14	3771-3776	after	_	_	_	_
27-15	3777-3780	red	abstract	new	appos	27-17[181_0]
27-16	3781-3782	–	_	_	_	_
27-17	3783-3796	near-infrared	abstract[181]	giv[181]	_	_
27-18	3797-3802	light	abstract|abstract[181]	giv|giv[181]	_	_
27-19	3803-3813	exposition	abstract[181]	giv[181]	_	_
27-20	3814-3815	.	_	_	_	_

#Text=The composite activities against two resistant E. coli strains were tested .
28-1	3816-3819	The	abstract[182]	new[182]	_	_
28-2	3820-3829	composite	abstract[182]	new[182]	_	_
28-3	3830-3840	activities	abstract[182]	new[182]	_	_
28-4	3841-3848	against	abstract[182]	new[182]	_	_
28-5	3849-3852	two	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
28-6	3853-3862	resistant	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
28-7	3863-3865	E.	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
28-8	3866-3870	coli	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
28-9	3871-3878	strains	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
28-10	3879-3883	were	_	_	_	_
28-11	3884-3890	tested	_	_	_	_
28-12	3891-3892	.	_	_	_	_
